Bank of America Securities: Downgrade Shijiazhuang Pharmaceutical Group (01093) target price to HKD 8, rating "Underperform the Market"

LootboxPhobia · 2026-03-27T07:31:53+00:00

Cailian Press APP learned that Bank of America Securities issued a research report stating that CSPC Pharmaceutical Group(01093) reported a total revenue of 26 billion RMB last year, a year-on-year decrease of 10.4%(, and a net profit of 3.9 billion RMB, down 10.3%). The bank expects CSPC's total revenue from collaborations this year to exceed 10 billion RMB, and has adjusted its revenue forecasts for CSPC from 2023 to 2028, with increases of 0.4%, and decreases of 4.1% and 4.1% respectively. The earnings per share forecasts for each year have been lowered by 0.4%, 7.1%, and 22.3%. Its target price has been reduced from HKD 9.1 to HKD 8, maintaining its rating as "Underperform the Market."

LootboxPhobia

2026-03-27 07:31:53

Zhitong Finance APP learned that Bank of America Securities released a research report stating that Shanghai Pharmaceuticals Holding (01093) recorded a total revenue of 26 billion yuan last year, a year-on-year decrease of 10.4%, and a net profit of 3.9 billion yuan, a year-on-year decrease of 10.3%. The bank expects Shanghai Pharmaceuticals’ total revenue from collaborations to exceed 10 billion yuan this year, while adjusting its revenue forecasts for Shanghai Pharmaceuticals from this year to 2028, with increases of 0.4%, and decreases of 4.1% and 4.1%, respectively. The earnings per share estimates for each year have been lowered by 0.4%, 7.1%, and 22.3%, respectively. Its target price has been reduced from HKD 9.1 to HKD 8, maintaining its rating of “underperforming the market.”

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.